ATE166233T1 - Verwendung von substanzen in partikelform - Google Patents

Verwendung von substanzen in partikelform

Info

Publication number
ATE166233T1
ATE166233T1 AT91916129T AT91916129T ATE166233T1 AT E166233 T1 ATE166233 T1 AT E166233T1 AT 91916129 T AT91916129 T AT 91916129T AT 91916129 T AT91916129 T AT 91916129T AT E166233 T1 ATE166233 T1 AT E166233T1
Authority
AT
Austria
Prior art keywords
substances
particle form
diagnostic
vascularized
prophylaxis
Prior art date
Application number
AT91916129T
Other languages
English (en)
Inventor
Aaron Gershon Filler
Original Assignee
Syngenix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909020075A external-priority patent/GB9020075D0/en
Priority claimed from GB909027293A external-priority patent/GB9027293D0/en
Priority claimed from GB919100233A external-priority patent/GB9100233D0/en
Priority claimed from GB919100981A external-priority patent/GB9100981D0/en
Priority claimed from GB919102146A external-priority patent/GB9102146D0/en
Priority claimed from GB919110876A external-priority patent/GB9110876D0/en
Priority claimed from GB919116373A external-priority patent/GB9116373D0/en
Priority claimed from GB919117851A external-priority patent/GB9117851D0/en
Priority claimed from GB919118676A external-priority patent/GB9118676D0/en
Application filed by Syngenix Ltd filed Critical Syngenix Ltd
Application granted granted Critical
Publication of ATE166233T1 publication Critical patent/ATE166233T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Ceramic Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT91916129T 1990-09-14 1991-09-13 Verwendung von substanzen in partikelform ATE166233T1 (de)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB909020075A GB9020075D0 (en) 1990-09-14 1990-09-14 Contrast agents for magnetic resonance imaging of axonal transport
GB909023580A GB9023580D0 (en) 1990-09-14 1990-10-30 Contrast agents for magnetic resonance imaging of axonal transport
GB909027293A GB9027293D0 (en) 1990-09-14 1990-12-17 Ferrite particles for tracer imaging and treatment
GB919100233A GB9100233D0 (en) 1990-09-14 1991-01-07 Metal oxide particles for medical use
GB919100981A GB9100981D0 (en) 1990-09-14 1991-01-16 Metal oxide particles for medical use
GB919102146A GB9102146D0 (en) 1990-09-14 1991-01-31 Particles for delivery via vascular,lymphatic and neural routes
GB919110876A GB9110876D0 (en) 1990-09-14 1991-05-20 Particles for delivery via vascular lymphatic and neural routes
GB919116373A GB9116373D0 (en) 1990-09-14 1991-07-30 Affinity purified,filter sterilized,targeted nanoparticles for delivery by intraneural,vascular and lymphatic routes
GB919117851A GB9117851D0 (en) 1990-09-14 1991-08-19 Affinity purified, filter sterilized, targeted nanoparticles for delivery by intraneural, vascular, and lymphatic routes
GB919118676A GB9118676D0 (en) 1990-09-14 1991-08-30 Affinity purified,filter sterilized,targeted nanoparticles for delivery by intraneural,vascular,and lymphatic routes

Publications (1)

Publication Number Publication Date
ATE166233T1 true ATE166233T1 (de) 1998-06-15

Family

ID=27579385

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91916129T ATE166233T1 (de) 1990-09-14 1991-09-13 Verwendung von substanzen in partikelform

Country Status (6)

Country Link
EP (1) EP0548157B1 (de)
AT (1) ATE166233T1 (de)
AU (1) AU8514291A (de)
DE (1) DE69129463T2 (de)
IE (1) IE913240A1 (de)
WO (1) WO1992004916A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119762D0 (en) * 1991-09-16 1991-10-30 Filler Aaron G Particulate agents for nmt
US5225282A (en) * 1991-12-13 1993-07-06 Molecular Bioquest, Inc. Biodegradable magnetic microcluster comprising non-magnetic metal or metal oxide particles coated with a functionalized polymer
FR2775435B1 (fr) * 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
US6372722B1 (en) 2000-01-19 2002-04-16 Genteric, Inc. Method for nucleic acid transfection of cells
CN105381296A (zh) * 2015-12-09 2016-03-09 徐冉 一种治疗面瘫的祛风通络制剂及制法
CN105381222A (zh) * 2015-12-09 2016-03-09 徐冉 一种防治面肌痉挛的中药组合物及制备方法
CN105381294A (zh) * 2015-12-09 2016-03-09 徐冉 用于医治面神经麻痹的制剂及制法
CN105381295A (zh) * 2015-12-09 2016-03-09 徐冉 一种治疗面肌痉挛的制剂及制备方法
US10744212B2 (en) 2016-03-14 2020-08-18 General Electric Company Topical application of nerve labeling dyes for image-guided surgery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1268208A (en) * 1984-08-10 1990-04-24 Truman Brown Magnetic micro-particles as contrast agents in nuclear magnetic resonance imaging
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
GB8808305D0 (en) * 1988-04-08 1988-05-11 Nycomed As Compositions
JPH04501218A (ja) * 1988-08-04 1992-03-05 アドヴァンスド　マグネティックス　インコーポレーティッド 受容体媒介エンドサイト―シス型ｍｒｉ造影剤

Also Published As

Publication number Publication date
AU8514291A (en) 1992-04-15
IE913240A1 (en) 1992-02-25
DE69129463T2 (de) 1998-09-17
EP0548157B1 (de) 1998-05-20
EP0548157A1 (de) 1993-06-30
DE69129463D1 (de) 1998-06-25
WO1992004916A3 (en) 1992-08-20
WO1992004916A2 (en) 1992-04-02

Similar Documents

Publication Publication Date Title
EP0861667A3 (de) Partikelförmige Mittel
DE69010206T2 (de) Stabilisierte protein- oder peptidkonjugate.
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
DE68925974T2 (de) Konjugate zur steigerung der durchlässigkeit der gefässe
DE69104830D1 (de) Darreichnungsform zur verabreichnung eines antiparkinsonsmittel.
ES2188652T3 (es) Sistema de direccionado de farmacos, metodos de fabricacion y uso del mismo.
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
ATE96308T1 (de) Dosierform fuer verabreichung in der humanmedizin.
FI875533A (fi) Insulinpreparat foer non-parenteral dosering.
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
ATE308545T1 (de) Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE69129463T2 (de) Verwendung von substanzen in partikelform
SE8602743L (sv) Bruksferdiga injektionslosningar innehallande en antitumorantracyklinglykosid
ES2114073T3 (es) Regeneracion del higado inducida por morfogenes.
SU556805A1 (ru) Способ введени лекарственных веществ
GB9023701D0 (en) Medical treatment
ATE173405T1 (de) Arzneimittel auf basis von hyaluronsäure
YU189891A (sh) Kratki peptidi s insulinskim dejstvom, postupak za njihovo dobijanje, farmaceutski preparati, kao i postupak za njihovo dobijanje
GB2198351B (en) Improvements in or relating to the use of epidermal growth factor for enhancing the uptake of iron in vivo.
Kelimbetov et al. Lincomycin concentration in the blood and tissues when administered by electrophoresis in children with acute and chronic hematogenic osteomyelitis
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
ZA887181B (en) A method for the preparation of a pharmaceutical curative for the veterinary and humane medicine,with antiviral and antitumoral effect
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
CA2000479A1 (en) Vasopermeability-enhancing conjugates

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties